Vilon: Research & Studies
Scientific evidence, clinical trials, and research findings
📌TL;DR
- •2 clinical studies cited
- •Overall evidence level: low
- •8 research gaps identified
Research Studies
A synthetic dipeptide vilon (L-Lys-L-Glu) inhibits growth of spontaneous tumors and increases life span of mice
Khavinson VKh, Anisimov VN (2000) • Doklady Biological Sciences
Chronic subcutaneous vilon administration to female CBA mice from 6 months of age inhibited spontaneous tumor growth and extended lifespan. No adverse effects on development or reproductive function were observed.
Key Findings
- Inhibited growth of spontaneous tumors in CBA mice
- Increased lifespan of treated mice compared to controls
- Long-term administration was safe with no adverse developmental effects
Limitations: Single research group; Russian-language journal; small sample size typical of early Russian peptide bioregulator studies; no independent replication; detailed methodology not available in English
Effect of vilon on biological age and lifespan in mice
Khavinson VKh, Anisimov VN (2000) • Bulletin of Experimental Biology and Medicine
Subcutaneous vilon administration to female CBA mice from 6 months of age increased physical activity and endurance, decreased body temperature, prolonged lifespan, and prevented spontaneous neoplasm development. No effect on estrous function or free radical processes.
Key Findings
- Increased physical activity and endurance in treated mice
- Decreased body temperature (potential caloric restriction-like effect)
- Prolonged lifespan and prevented spontaneous neoplasm development
- No effect on age-related changes in estrous function or free radical processes
- No adverse effects on animal development with chronic administration
Limitations: Single research group; single mouse strain (CBA females); no dose-response study; free radical and estrous function endpoints not affected; mechanism not elucidated
Unlock full research citations
Free access to all clinical studies, citations, and evidence summaries.
150+ peptide profiles · 30+ comparisons · 18 research tools
Community Experience Data
See how community outcomes align with (or diverge from) the research findings above.
Based on 15+ community reports
View community protocolsExplore research gaps across all peptides → | View clinical trial pipeline →
🔍Research Gaps & Future Directions
- •No independent replication of lifespan or tumor-inhibiting effects outside the Khavinson research group
- •No pharmacokinetic studies characterizing absorption, distribution, metabolism, or excretion in any species
- •Specific molecular target or receptor for vilon has not been identified
- •No clinical trials registered with Western regulatory agencies (ClinicalTrials.gov, EudraCT)
- •Mechanism of tissue selectivity for a simple dipeptide not explained
- •Oral bioavailability of intact vilon dipeptide not demonstrated
- •Dose-response relationship not characterized in vivo
- •Chromatin remodeling effects not validated by independent groups using modern epigenomic methods (ChIP-seq, ATAC-seq)
Research Overview#
Vilon research has been conducted primarily by Professor Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology over approximately two decades. The research covers geroprotective effects in mice, chromatin remodeling in human cells, and immunomodulatory activity in thymic cell cultures. The evidence level is classified as low due to the near-complete dependence on a single research group and the absence of independent replication.
Geroprotective Research#
Tumor Inhibition and Lifespan Extension (Dokl Biol Sci 2000)#
Khavinson and Anisimov (PMID 10944717) reported the foundational geroprotective study:
- Model: Female CBA mice, chronic SC vilon from age 6 months
- Key finding: Vilon inhibited spontaneous tumor growth and extended lifespan
- Safety: No adverse effects reported during long-term administration
Biological Age and Lifespan (Bull Exp Biol Med 2000)#
The companion study (PMID 11140587) provided additional physiological data:
- Vilon increased physical activity and endurance
- Decreased body temperature (potentially mimicking caloric restriction effects)
- Prolonged lifespan and prevented spontaneous neoplasms
- No effect on estrous function or free radical processes
- Safety confirmed with chronic administration
These studies form the core evidence for vilon as a geroprotective agent. However, they represent a single mouse strain from a single laboratory, and the magnitude of lifespan extension and detailed survival curves have not been widely available in English-language publications.
Epigenetic Research#
Chromatin Remodeling#
The Khavinson group has published several studies on vilon's effects on chromatin structure:
- Lymphocytes from aged donors: Vilon reportedly induced deheterochromatinization (unrolling of condensed chromatin) in blood lymphocytes from elderly subjects
- Proposed mechanism: Reactivation of genes silenced by age-related heterochromatin accumulation
- Nucleolus organizer regions: Vilon activated synthetic processes by reactivating ribosomal genes through deheterochromatinization of nucleolus organizer regions
These chromatin studies are conceptually interesting but were conducted using older cytogenetic methods (chromosome staining). Modern epigenomic techniques (ChIP-seq, ATAC-seq, bisulfite sequencing) have not been applied to validate these findings.
Gene Expression#
In human embryonic mesenchymal stem cells, vilon was reported to regulate expression of:
- IGF1: Growth factor involved in aging and longevity
- FOXO1: Transcription factor in longevity and stress resistance pathways
- TERT: Telomerase reverse transcriptase, involved in telomere maintenance
- TNKS2: Tankyrase 2, involved in telomere regulation
- NFkB: Central inflammatory signaling pathway
While these gene targets are relevant to aging biology, the studies did not demonstrate a specific binding target or signaling cascade explaining how a 275 Da dipeptide could selectively regulate these diverse genes.
Immunomodulation Research#
Vilon has been studied for immunomodulatory effects:
- Enhanced immune cell differentiation in thymic cell cultures
- Modulated expression of CD markers on T lymphocytes
- Proposed to support thymic function during age-related involution
The immunomodulatory studies are consistent with vilon's origin as a thymus-derived peptide sequence but are predominantly in vitro and from the same research group.
Evidence Quality Assessment#
| Evidence Criterion | Assessment | Details |
|---|---|---|
| Study design | Preclinical only | Mouse lifespan studies and in vitro experiments |
| Publication quality | Low-Moderate | Mix of Russian journals and low-impact international journals |
| Independent replication | Absent | Nearly all data from Khavinson group |
| Mechanism | Poorly defined | No specific receptor or signaling pathway identified |
| In vivo efficacy | Limited | Mouse lifespan data from single strain and laboratory |
| Pharmacokinetics | Absent | No ADME data in any species |
| Clinical translation | Not initiated | No Western regulatory clinical trials |
| Modern validation | Absent | Epigenetic claims not validated by ChIP-seq/ATAC-seq |
Critical Assessment#
Vilon research illustrates the challenges of evaluating peptide bioregulators from the Khavinson program:
- Promising concept: The idea that tissue-specific short peptides regulate gene expression is biologically plausible
- Execution concerns: Nearly all evidence from a single group, limited methodological detail in English, and low-impact publication venues
- Mechanistic gap: No identified receptor, no crystal structure, no validated signaling pathway for a 275 Da dipeptide
- Translation barrier: Without independent replication, pharmacokinetic data, and mechanism identification, clinical development by Western standards cannot proceed
Related Reading#
Frequently Asked Questions About Vilon
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.